Considerations on equity in management of end-stage kidney disease in low- and middle-income countries.

Clicks: 243
ID: 99981
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Achievement of equity in health requires development of a health system in which everyone has a fair opportunity to attain their full health potential. The current, large country-level variation in the reported incidence and prevalence of treated end-stage kidney disease indicates the existence of system-level inequities. Equitable implementation of kidney replacement therapy (KRT) programs must address issues of availability, affordability, and acceptability. The major structural factors that impact equity in KRT in different countries are the organization of health systems, overall health care spending, funding and delivery models, and nature of KRT prioritization (transplantation, hemodialysis or peritoneal dialysis, and conservative care). Implementation of KRT programs has the potential to exacerbate inequity unless equity is deliberately addressed. In this review, we summarize discussions on equitable provision of KRT in low- and middle-income countries and suggest areas for future research.
Reference Key
van-biesen2020considerationskidney Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Van Biesen, Wim;Jha, Vivekanand;Abu-Alfa, Ali K;Andreoli, Sharon P;Ashuntantang, Gloria;Bernieh, Bassam;Brown, Edwina;Chen, Yuqing;Coppo, Rosanna;Couchoud, Cecile;Cullis, Brett;Douthat, Walter;Eke, Felicia U;Hemmelgarn, Brenda;Hou, Fan Fan;Levin, Nathan W;Luyckx, Valerie A;Morton, Rachael L;Moosa, Mohammed Rafique;Murtagh, Fliss E M;Richards, Marie;Rondeau, Eric;Schneditz, Daniel;Shah, Kamal D;Tesar, Vladimir;Yeates, Karen;Garcia Garcia, Guillermo;
Journal kidney international supplements
Year 2020
DOI 10.1016/j.kisu.2019.11.004
URL
Keywords
Social justice equity end-stage kidney disease reimbursement ethical framework kidney replacement therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.